Abstract
Recently, the relationship between advanced glycation end products (AGEs) and erectile dysfunction (ED) has been reported. The present study aimed to investigate whether a combination of an AGE cross-link breaker (alagebrium/ALT-711) and sildenafil could enhance the erectile capacity in streptozotocin (STZ) diabetic rats. Additionally, we assessed the effect of that treatment option on some molecules that have been suggested to have crucial roles in AGE-related ED pathways. Four groups of animals were utilized: (1) age-matched control rats, (2) STZ-induced diabetic rats (40 mg kg−1 i.p.), (3) STZ rats+sildenafil (5 mg kg−1 p.o.), (4) STZ rats treated with a combination of sildenafil (5 mg kg−1 p.o)+alagebrium/ALT-711 (10 mg kg−1 p.o.) for the final 1 month of the 2 months of diabetes period. At 2 months after i.p. injection of STZ, all animals underwent cavernosal nerve stimulation (CNS) to assess erectile function. Penile tissue AGEs, MDA (malondialdehyde), cyclic guanosine monophosphate (cGMP) (ELISA), endothelial nitric oxide (NO) synthase (eNOS), inducible NO synthase (iNOS) (western blot), nuclear factor (NF)-κB, mitogen-activated protein (MAP) kinase (immunohistochemistry) and apoptosis (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling) analyses were performed in all groups of rats. STZ diabetic rats had a significant decrease in erectile function as determined by the peak intracavernosal pressure (ICP) and total ICP (area under the erectile curve) after CNS when compared with control rats (P<0.05). The increase in both ICP and area under the erectile curve of STZ diabetic rats treated with a combination of sildenafil+alagebrium/ALT-711 as well as in STZ diabetic rats treated with sildenafil alone was significantly greater than STZ diabetic rats. Additionally, combination treatment decreased AGE, MDA, iNOS, NF-κB, MAP kinase and apoptosis levels, whereas it preserved cGMP contents in diabetic penile tissue. Decreased AGE, MDA, iNOS, NF-κB, MAP kinase and increased cGMP levels at the combination (sildenafil+alagebrium/ALT-711) therapy group increased both the peak ICP and total ICP to CNS in the STZ diabetic rats, which was similar to the response observed in control rats. These results may explain the role of AGEs in diabetes-related ED and the effect of an AGE cross-link breaker alagebrium/ALT-711+sildenafil therapy on some critical molecules related to AGE-related ED pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJG . Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24 (Suppl): S17–S37.
Moore CR, Wang R . Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8: 675–684.
Bivalacqua TJ, Usta MF, Kendirci M, Pradhan L, Alvarez X, Champion HC et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2009; 2: 187–198.
Usta MF, Bivalacqua TJ, Yang DY, Ramanitharan A, Sell DR, Visvanathan A et al. protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003; 170: 1437–1442.
Usta MF, Bivalacqua TJ, Koksal IT, Toptas B, Surmen S, Hellstrom WJG . The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU Int 2004; 94: 429–432.
Usta MF, Kendirci M, Gür S, Foxwell NA, Bivalacqua TJ, Cellek S et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006; 3: 242–252.
Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421–426.
De Young L, Yu D, Freeman D, Brock GB . Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Imp Res 2003; 15: 347–354.
Kasai K, Nakamura T, Kase N, Hiraoka T, Suziki R, Koqure F et al. Increased glycosylation of proteins from cataractous lenses in diabetes. Diabetologia 1983; 25: 36–38.
Wasowicz W, Neve J, Peretz A . Optimized steps in fluorometric determination of thiobarbituric acid reactive substances in serum: importance of extraction pH and influence of sample preservation and storage. ClinChem 1993; 39: 2522–2526.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ . Protein measurement with the Folin phenol reagent. J BiolChem 1951; 193: 265–275.
Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Imp Res 2004; 16: 21–29.
Akingba AG, Burnett AL . Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diabetic rat. Mol Urol 2001; 5: 189–197.
Usta MF, Tuncer M, Baykal A, Ciftcioglu MA, Erdogru T, Koksal IT et al. Impact of chronic renal failure and peritoneal dialysis fluids on advanced glycation end product and iNOS levels in penile tissue: an experimental study. Urology 2002; 59: 953–957.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Eng J Med 1998; 338: 1397–1404.
Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005; 28: 260–266.
Park K, Ryu KS, Li WJ, Kim SW, Paick JS . Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol 2008; 53: 1282–1289.
De Young LX, Domes T, Lim K, Carson J, Brock GB . Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008; 54: 213–220.
Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS and eNOS. Urology 1997; 50: 1016–1026.
Bierhaus A, Ziegler R, Nawroth PP . Molecular mechanisms of diabetic angiopathy-clues for innovative therapeutic interventions. Horm Res 1998; 50 (Suppl 1): 1–5.
Liu J, Zhao S, Tang J, Li Z, Zhong T, Liu Y et al. Advanced glycation end products and lipopolysaccharide synergistically stimulate proinflammatory cytokine/chemokine production in endothelial cells via activation of both mitogen-activated protein kinases and nuclear factor-kappaB. FEBS J 2009; 276: 4598–4606.
Nangle MR, Cotter MA, Cameron NE . Correction of nitrergic neurovascular dysfunction in diabetic mouse corpus cavernosum by p38 mitogen-activated protein kinase inhibition. Int J Imp Res 2006; 18: 258–263.
Angulo J, Peiró C, Cuevas P, Gabancho S, Fernández A, González-Corrochano R et al. The novel antioxidant, AC3056 (2,6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic men. J Sex Med 2009; 6: 373–387.
Alici B, Gumustas H, Ozkara H, Akkus E, Demirel G, Yencilek F et al. Apoptosis in the erectile tissues of diabetic and healthy rats. BJU Int 2000; 85: 326–329.
Yamanaka M, Shirai M, Shiiina H, Tanaka Y, Tsujimura A, Matsumia K et al. Diabetes induced erectile dysfunction and apoptosis in penile crura are recovered by insulin treatment in rats. J Urol 2003; 170: 291–297.
Gonzales-Cadavid NF, Rajfer J . The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des 2005; 11: 4041–4046.
Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S . Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2353–2362.
Cellek S, Qu W, Schmidt AM, Moncada S . Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia 2004; 47: 331–339.
Acknowledgements
This work was supported by the Akdeniz University Research Foundation. ALT-711 and sildenafil were kindly provided by Alteon, Parsipanny, NJ, USA and by Pfizer, New York, NY, USA, respectively. Part of the present study was awarded as a ‘Basic Science Abstract Award Recipient’ during the SMS Meeting, Las Vegas, NV, USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gurbuz, N., Sagdic, G., Sanli, A. et al. Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. Int J Impot Res 24, 114–121 (2012). https://doi.org/10.1038/ijir.2011.54
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2011.54
Keywords
This article is cited by
-
The therapeutic effect of ALT-711 on erectile function in rats treated with high-level AGEs (advanced glycation end products) containing diet
International Journal of Impotence Research (2022)
-
Pomegranate juice causes a partial improvement through lowering oxidative stress for erectile dysfunction in streptozotocin-diabetic rat
International Journal of Impotence Research (2016)
-
Targeting advanced glycation with pharmaceutical agents: where are we now?
Glycoconjugate Journal (2016)